High-impact translational research is a top priority at Cleveland Clinic Cancer Center.
Cleveland Clinic physicians and scientists have developed new treatments for, and uncovered key information about, cancer cells that have resulted in significant changes in the way patients are screened, diagnosed and treated. In recognition of these and other contributions, U.S. News and World Report has ranked Cleveland Clinic as one of the top 10 cancer centers in the nation for the last several years.
At Cleveland Clinic, we believe “The Science is the Care.” We are home to one of the most robust cancer research enterprises in the United States, encompassing basic, clinical and translational research.
Regrettably, the extramural funding to support such projects is harder and harder to obtain. We are extremely fortunate to benefit from VeloSano. Every mile that our participants ride and every dollar that our donors give is a reminder of our obligation to leverage their incredible generosity, by pursuing research that will make a difference in our patients’ lives.
Below you will find additional details about how the funds are allocated and the different focus areas. We encourage you to check back in the Spring of 2016 for the VeloSano 2 Annual Report, which will include specifics of the research projects funded from the second annual VeloSano, as well as updates on the research that was funded from the inaugural ride.
Participating in VeloSano is fun, exciting and immensely gratifying. I invite you to join us in Cleveland for VeloSano 3: July 29–31.
Brian J. Bolwell, MD, FACP
Chairman, Taussig Cancer Institute at Cleveland Clinic
Medical Chairman, VeloSano